Guardian Pharmacy Services, Inc. Class A stock analysis
Want to see GRDN full AI Analyst Report?
Guardian Pharmacy Services, Inc. Class A (GRDN) Stock Price & Analysis
GRDN Stock Chart & Stats
- Day’s Range
- $49.20 - $50.80
- 52-Week Range
- $26.34 - $50.80
- Previous Close
- $49.43
- Volume
- N/A
- Average Volume (3M)
- 481.42K
- Market Cap
- $3.19B
- Enterprise Value
- $2.53B
- Total Cash (Recent Filing)
- $119.66M
- Total Debt (Recent Filing)
- $35.59M
- Price to Earnings (P/E)
- 42.5
- Beta
- 0.45
- Next Earnings
- Mar 31, 2027 (Est.)
- EPS Estimate
- 0.45
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Resident And Prescription Volume Growth
Growth in residents and prescriptions indicates increasing utilization of Guardian’s pharmacy platform within its target care settings. Higher recurring volume can deepen facility relationships, improve operating leverage, and support durable expansion as the company adds customers and locations.
Debt-free Balance Sheet And Cash Generation
A debt-free balance sheet and substantial cash position provide financial flexibility to fund acquisitions, greenfield pharmacies, and operating investment without relying on external financing. This strengthens resilience and allows management to pursue growth while avoiding direct exposure to borrowing costs.
Raised Outlook And Expansion Runway
Raised revenue and EBITDA guidance reflects stronger operating performance, improved reimbursement, and market expansion initiatives. The outlook also excludes additional acquisitions beyond those completed, suggesting the existing platform and identified expansion efforts can support continued earnings growth.
Bears Say
IRA-related Pricing Pressure
IRA-related drug price reductions are already weighing on reported revenue and create an ongoing reimbursement risk for the business. Even if underlying prescription demand remains healthy, policy-driven pricing changes can limit top-line growth and complicate forecasting across future periods.
Expansion Investments Weigh On Margins
Guardian’s growth strategy requires continued investment in acquisitions and new pharmacies before those cohorts mature. This creates recurring margin dilution and earnings variability, meaning strong volume growth may not translate immediately into proportional profitability while expansion remains active.
Elevated Operating Costs
The delivery-intensive model remains exposed to elevated fuel and broader operating costs. Persistent expense pressure can absorb part of the benefit from reimbursement improvements and volume growth, making margin preservation dependent on purchasing, route, and operating efficiencies.
Guardian Pharmacy Services, Inc. Class A News
Guardian Pharmacy Services’ Strong Results and Growth Prospects Support Unchanged $47 Price Target and Buy Rating
Bank of America Securities analyst Allen Lutz has reiterated their bullish stance on GRDN stock, giving a Buy rating today. Allen Lutz’s rating is based on Guardian Pharmacy Services’ strong
Guardian Pharmacy acquires Van’s Institutional Pharmacy, terms not disclosed
Guardian Pharmacy (GRDN) Services announced the acquisition of Van’s Institutional Pharmacy, an LTC pharmacy based in Martin, Tenn. The addition grows Guardian’s Tennessee operations to five pharmacies in Memphis, Shelbyville,
Guardian Pharmacy Services: Buy Rating Reiterated as Nautilus Acquisition Supports Scalable, Capital-Light Growth; Price Target Maintained at $47
Analyst Allen Lutz of Bank of America Securities reiterated a Buy rating on Guardian Pharmacy Services, Inc. Class A, retaining the price target of $47.00. Allen Lutz has given his
Guardian Pharmacy acquires assets of Nautilus Pharmacy, terms not disclosed
Guardian Pharmacy (GRDN) Services announced the acquisition of assets from Tennessee-based Nautilus Pharmacy, including prescription files, related pharmacy inventory, and certain fixed assets. “Guardian has built its business around the
Guardian Pharmacy reports Q2 adjusted EPS 29c, consensus 26c
Reports Q2 revenue $351.8M, consensus $340.45M. “Guardian delivered another strong quarter, with continued momentum across our local markets,” said Fred Burke, President and Chief Executive Officer. “While IRA-related pricing reductions
GRDN FAQ
What was Guardian Pharmacy Services, Inc. Class A’s price range in the past 12 months?
What is Guardian Pharmacy Services, Inc. Class A’s market cap?
When is Guardian Pharmacy Services, Inc. Class A’s upcoming earnings report date?
How were Guardian Pharmacy Services, Inc. Class A’s earnings last quarter?
Is Guardian Pharmacy Services, Inc. Class A overvalued?
Does Guardian Pharmacy Services, Inc. Class A pay dividends?
What is Guardian Pharmacy Services, Inc. Class A’s EPS estimate?
How many shares outstanding does Guardian Pharmacy Services, Inc. Class A have?
What happened to Guardian Pharmacy Services, Inc. Class A’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Guardian Pharmacy Services, Inc. Class A?
What is the TipRanks Smart Score and how is it calculated?
Guardian Pharmacy Services, Inc. Class A Stock Smart Score
Company Description
Guardian Pharmacy Services, Inc. Class A
Guardian Pharmacy Services, Inc. operates as a pharmaceutical service provider, delivering an extensive array of tech-driven solutions. These services are specifically crafted to enhance the care of residents within long-term health care facilities (LTCFs) across the United States. The company specializes in offering personalized clinical assistance, efficient drug distribution, and comprehensive administrative support. These provisions are particularly beneficial for individuals in less acute long-term care environments, such as assisted living communities, behavioral health centers, and group homes. To bolster its operations, the company offers Guardian Compass, a platform that generates insightful dashboards from its extensive data warehouse. This tool enables its network of local pharmacies to effectively strategize, monitor performance, and refine their business processes. Furthermore, Guardian Pharmacy Services develops dedicated GuardianShield Programs for LTCFs. The company was established in 2003 and is based in Atlanta, Georgia.
- Sector
- General
- Industry
- Medical - Care Facilities
- CEO
- Fred Burke
- Employees
- 3,600
- Website
- guardianpharmacy.com
- Address
- 300 Galleria Parkway SE, Atlanta, GA, 30339, US
Guardian Pharmacy Services, Inc. Class A (GRDN) Earnings & Revenues
GRDN Earnings Call
Earnings Call SentimentPositive
The call was strongly positive overall. Guardian reported solid operating growth, significant Adjusted EBITDA and net income increases, improved gross profit and margins, multiple expansion initiatives, an active acquisition pipeline, a debt-free balance sheet, and raised full-year guidance. The main challenges were the 1.7% reported revenue decline caused by IRA-related drug price reductions, elevated fuel and operating costs, onboarding costs, margin effects from ongoing expansion investments, and uncertainty around future policy developments. Management nevertheless characterized demand, market opportunity, reimbursement trends, and the company's financial position favorably.
View all GRDN earnings summariesGRDN Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 1 | 6 |
| Technical Analysis | 3 | 1 | 6 |
| Moving Averages | 12 | 0 | 0 |








